Page 1, 2, 3
MAP therapy has been successful in many patients with varying types of tachycardia and dysrhythmias over its years of use. We have successfully combined it with other natural, medical, and surgical interventions to equal success. There are patients who are nonresponders to MAP, but they can be identified and redirected to other therapies within a few weeks of MAP trial. MAP is our first line natural treatment for tachydysrhythmias, especially when comorbidities such as dyslipidemia or metabolic syndrome exist.
We have presented only a small sample of straightforward case data here. We will continue to publish on the successful use of MAP in more complex cases beginning with an upcoming peer-reviewed case series. Following that, we intend to begin comparative effectiveness trials of MAP plus usual therapy (conventional pharmaceutical rate and rhythm control agents) versus usual therapy plus placebo. The MAP is a promising treatment option that warrants further investigation.
To contact the authors or for further information:
Dr. Martin Milner and Dr. Jeremy Mikolai
Heart & Lung Wellness Program
Center for Natural Medicine Inc. (CNM)
1330 SE Cesar E Chavez Blvd.
Portland, Oregon 97214
These authors have no financial conflicts of interest to declare.
1.Milner M. Critical decision making in the use of key cardiovascular drugs, slides 44–50. Presented at: British Columbia Naturopathic Association Conference 2010. Proceedings of the 9th Advanced Natural Medicine Conference. 2010 Sep 26; Vancouver, Canada.
2.Vincenzi. The Heart: an important ANS effector [Web page]. University of Washington, School of Medicine. 1996; updated 2004. Accessed 2012 Oct 22. http://courses.washington.edu/chat543/cvans/sfp/effector.html.
3.Klabunde RE. Norepinephrine, Epinephrine and Acetylcholine - Synthesis, Storage, Release and Metabolism [Web page]. Ohio College of Osteopathic Medicine. 1998; updated 2008. Accessed 2012 Oct 22. http://www.cvpharmacology.com/norepinephrine.htm.
4.Champe PC, Harvey RA, Ferrier DR. Biochemistry. 3rd ed. Baltimore: Lippincott, Williams & Wilkins; 2005:104,188–192.
5.Higdon J, Drake VJ. Pantothenic acid [Web page]. Linus Pauling Institute. 2004; updated 2008. Accessed 2012 Oct 22. http://lpi.oregonstate.edu/infocenter/vitamins/pa.
6.Blusztajn JK. Choline, a vital amine. Science. 1998;281(5378):794–795.
7.Higdon J, Drake VJ. Choline [Web page]. Linus Pauling Institute. 2003. Updated 2008; accessed 2012 Oct 22. http://lpi.oregonstate.edu/infocenter/vitamins/pa.
8.Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. Nutr Rev. 2009;Nov;67(11):615–623.
9.Hasler CM. The changing face of functional foods. J Nutr. 2000;19;(5 Suppl):499S–506S.
10. Bidulescu A, Chambless LE, Siega-Riz AM, Zeisel SH, Heiss G. Repeatability and measurement error in the assessment of choline and betaine dietary intake: the Atherosclerosis Risk in Communities (ARIC) study. Nutr J. 2009;8(1):14.
11. Fischer LM, da Costa K, Kwock L, Galanko J, Zeisel SH. Dietary choline requirements of women: effects of estrogen and genetic variation. Am J Clin Nutrition. 2010;92(5):1113–1119.
12. Shils M, Olson JA, Shike M, Ross AC, eds. Modern Nutrition in Health and Disease. 9th ed. Baltimore: Williams & Wilkins; 1999;513–523.
13. Champe PC, Harvey RA, Ferrier DR. Biochemistry. 3rd ed. Baltimore: Lippincott, Williams & Wilkins; 2005:261–263.
14. Zeisel SH. Choline: critical role during fetal development and dietary requirements in adults. Annu Rev Nutr. 2006;26:229–250.
15. Kohlmeier M, da Costa KA, Fischer LM, Zeisel SH. Genetic variation of folate-mediated one-carbon transfer pathway predicts susceptibility to choline deficiency in humans. Proc Natl Acad Sci USA 2005;102(44):16025–16030.
16. da Costa KA, Kozyreva OG, Song J, Galanko JA, Fischer LM, Zeisel SH. Common genetic polymorphisms affect the human requirement for the nutrient choline. FASEB J. 2006;20;(9):1336–1344.
17. Fernstrom JD. Effects on the diet on brain neurotransmitters. Metabolism. 1977;Feb;26(2):207–223.
18. Lamb S. Precursor loading for monoamines in neurological disease. J Neurosurg Nurs. 1983 Aug;15(4):228–233.
19. Hinz M, Stein A, Uncini T. Monoamine depletion by reuptake inhibitors. Drug Healthc Patient Saf. 2011;3:69–77.
20. Hinz M, Stein A, Uncini T. Amino acid management of Parkinson's disease: a case study. Int J Gen Med. 2011;Feb 28;4:165–174.
21. Hinz M, Stein A, Neff R, Weinberg R, Uncini T. Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation. Neuropsychiatr Dis Treat. 2011;Jan 26;7:31–38.
22. Trachte GJ, Uncini T, Hinz M. Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population. Neuropsychiatr Dis Treat. 2009;5:227–235.
23. Hayashi H, Kobayashi A, Terada H, et al. Effects of pantethine on action potential of canine papillary muscle during hypoxic perfusion. Jpn Heart J. 1985 Mar;26(2):289–296.
24. Valora N, Floridi S, Pranzetti P, Mei V. Electrocardiogram changes in the rat by coenzyme A action. Boll Soc Ital Biol Sper. 1984 Feb 28;60(2):231–235.
25. Bonnet D, Martin D, Pascale De Lonlay, et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation. 1999 Nov 30;100(22):2248–2253.
26. Yamada KA, Kanter EM, Newatia A. Long-chain acylcarnitine induces Ca2+ efflux from sacrcoplasmic reticulum. J Cardiovasc Pharmacol. 2000 Jul;36(1):14–21.
27. DaTorre SD, Creer MH, Pogwizd SM, Corr PB. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol. 1991 Feb;23 Suppl 1:11–22.
28. Tamargo J, Caballero R, Gómez R, Núñez L, Vaquero M, Delpón E. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacol Ther. 2007 Apr;114(1):107–126.
29. Fang WT, Li HJ, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2012 Nov;74(5):744–756.
30. Lee JE, Jacques PF, Dougherty L, et al. Are dietary choline and betaine intakes determinants of total homocysteine concentration? Am J Clin Nutr. 2010 May;91(5):1303–1310.
31. Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis. 2011 Feb;34(1):3–15.
32. Atkinson W, Slow S, Elmslie J, Lever M, Chambers ST, George PM. Dietary and supplementary betaine: effects on betaine and homocysteine concentrations in males. Am J Clin Nutr. 2008 Mar;87(3):577–585.
33. Gupta SK, Gaur SN. A placebo controlled trial of two dosages of LPC antagonist-choline in the management of bronchial asthma. Indian J Chest Dis Allied Sci. 1997 39:149–156.
34. Gaur SN, Agarwal G, Gupta SK. Use of LPC antagonist, choline, in the management of bronchial asthma. Indian J Chest Dis Allied Sci. 1997 39:107–113.
35. Shaw GM, Carmichael SL, Yang W, et al. Periconceptional dietary intake of choline and betaine and neural tube defects in offspring. Am J Epidemiol. 2004.160:102–109.
36. Poly C, Massaro JM, Seshadri S, et al. The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham offspring cohort. Am J Clin Nutr. 2011 Dec;94(6):1584–1591.
37. Buchman AL, Sohel M, Brown M, et al. Verbal and visual memory improve after choline supplementation in long-term total parenteral nutrition: a pilot study. JPEN J Parenter Enteral Nutr. 2001 Jan–Feb;25(1):30–35.
38. Arenth PM, Russell KC, Ricker JH, Zafonte RD. CDP-choline as a biological supplement during neurorecovery: a focused review. PM R. 2011 Jun;3(6 Suppl 1):S123–S133.
39. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005 Apr18;(2):CD000269.
40. Zeisel SH. Choline: an essential nutrient for humans. Nutrition. 2000;16(7–8):669–671.
41. daCosta KA, Fischer LM, Kwock L, et al. Sex and menopausal status influence human dietary requirements for the nutrient choline. Am J Clin Nutr. 2007;85(5):1275–1285.
42. Resseguie M, Song J, Niculescu MD, da Costa KA, Randall TA, Zeisel SH. Phosphatidylethanolamine N-methyltransferase (PEMT) gene expression is induced by estrogen in human and mouse primary hepatocytes. FASEB J. 2007;21(10):2622–2632.
43. Park CS, Cho K, Bae DR, et al. Methyl-donor nutrients inhibit breast cancer cell growth. In Vitro Cell Dev Biol Anim. 2008 Jul–Aug;44(7):268–272.
44. Ferguson LR, Karunasinghe N, Philpott M. Epigenetic events and protection from colon cancer in New Zealand. Environ Mol Mutagen. 2004;44(1):36–43.
45. Brewster AM, Patterson SL, Forman MR, et al. Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila). 2010 Aug;3(8):1044–1048.
46. Kelly GS. Nutritional and botanical interventions to assist with the adaptation to stress. Altern Med Rev. 1999 Aug;4(4):249–265.
47. Houston M. The role of nutraceutical supplements in the treatment of dyslipidemia. J Clin Hypertens (Greenwich). 2012 Feb;14(2):121–132.
48. Rumberger JA, Napolitano J, Azumano I, Kamiya T, Evans M. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. Nutr Res. 2011 Aug;31(8):608–615.
49. Horváth Z, Vécsei L. Current medical aspects of pantethine. Ideggyogy Sz. 2009 Jul 30;62(7–8):220–229.
50. Pins JJ, Keenan JM. Dietary and nutraceutical options for managing the hypertriglyceridemic patient. Prog Cardiovasc Nurs. 2006 Spring;21(2):89–93.
51. Agrati AM, Ambrosi G, Ferraro G, Palmieri. Gemfibrozil efficacy vs pantethine in dyslipoproteinemic patients: a controlled study. Curr Ther Res. 1989;45:650–663.
52. Jellin JM, ed. Choline [Web page]. Natural Medicines Comprehensive Database. 1995. Updated 2011; accessed 2012 Oct 22. Available at http://naturaldatabase.therapeuticresearch.com.
53. Jellin JM, ed. Pantethine [Web page]. Natural Medicines Comprehensive Database. 1995. Updated 2012; accessed 2012 Oct 22. Available at http://naturaldatabase.therapeuticresearch.com.
54. Prisco D, Rogasi PG, Matucci M, et al. Effect of oral treatment with pantethine on platelet and plasma phospholipids in IIa hyperlipoproteinemia. Angiology. 1987;38:241–247.
55. McNamara JO, Carwile S, Hope V, et al. Effects of oral choline on human complex partial seizures. Neurology. 1980;30:1334–1336.
56. Cho E, Willett WC, Colditz GA, et al. Dietary choline and betaine and the risk of distal colorectal adenoma in women. J Natl Cancer Inst. 2007;99:1224–1231.
57. Food and Nutrition Board, Institute of Medicine. Choline. In: Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, D.C.: National Academies Press; 1998:390–422.
Jeremy Mikolai, ND, is the cofounder of the Naturopathic Institute of Cardiovascular and Pulmonary Medicine (NICVM). He is the attending physician in cardiovascular and pulmonary medicine at the National College of Natural Medicine (NCNM) and co-attending physician in the Heart & Lung Wellness program at the Center for Natural Medicine (CNM), both in Portland, OR. He is in his third year as the Heart & Lung Resident under the mentorship of Dr. Martin Milner at CNM and is the chief resident for 2012–2013 at NCNM. Dr. Mikolai is active in research and is an adjunct faculty member in the Masters of Science in Integrative Medicine Research (MSiMR) program at the Helfgott Research Institute at NCNM. He is actively working to create the first ND fellowship in cardiology.
Martin Milner, ND, has been in private practice since 1983 and is the medical director of the Center for Natural Medicine, Inc. CNM functions both as an integrated group medical practice and as a teaching clinic of NCNM. CNM is also active in clinical trials and research. Dr. Milner is the professor of cardiovascular and pulmonary medicine at NCNM and has been since 1986. He continues to supervise and mentor 48 ND student interns per year in the Heart & Lung Wellness Program, which he has maintained since 1999. He trains two ND residents each year, one who assists him in the Heart & Lung Wellness Program and one in his private practice. Dr. Milner is actively pursuing, with Dr. Mikolai, the creation of the first board certification program for NDs in Naturopathic Cardiology. In this regard, Dr. Milner and Dr. Mikolai cofounded the Naturopathic Institute of Cardiovascular and Pulmonary Medicine (NICVM.com), offering a rigorous curriculum of postgraduate education in naturopathic cardiovascular and pulmonary medicine.
Joseph DelGrosso, RD, (illustrator) is currently in his fourth year as a naturopathic medical student at the National College of Natural Medicine and a registered dietitian. He graduated magna cum laude in 2008 with a bachelor of science in dietetics from the State University of New York College at Oneonta, where he received the distinction of most outstanding dietetic student. He completed his dietetic internship at Queens College, New York.
Page 1, 2, 3